SARC032-SU2C April 7, 2021 A Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab With Radiotherapy and Adjuvant Pembrolizumab in Patients With High-Risk, Localized Soft Tissue Sarcoma of the Extremity TYPE OF SARCOMA: Soft Tissue Sarcoma of the ExtremityDRUG: PembrolizumabACCRUAL STATUS: Recruiting OVERALL STUDY PRINCIPAL INVESTIGATOR:David Kirsch, MD, PhDProfessor, Radiation Oncology / Professor of Pharmacology and Cell BiologyDuke University CLINICALTRIALS.GOV IDENTIFIER: NCT03092323 FOR STUDY DETAILS AND ELIGIBILITY CRITERIA: CLINICALTRIALS.GOV To learn more about this study view Dr. Kirsch’s SARC032 presentation at the 2021 SARC Semiannual Meeting: To contact the study research staff: CONTACT SARC